<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320312439140</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320312439140</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>RAAS Working Group Update</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Sarafidis</surname><given-names>Pantelis A</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312439140">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ruilope</surname><given-names>Luis M</given-names></name>
<xref ref-type="aff" rid="aff2-1470320312439140">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320312439140"><label>1</label>Academic Department of Renal Medicine, King’s College Hospital, London, UK</aff>
<aff id="aff2-1470320312439140"><label>2</label>Hypertension Unit, Hospital 12 de Octubre and Department of Preventive Medicine and Public Health, University Autonoma, Madrid, Spain Email: <email>ruilope@ad-hocbox.com</email></aff>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>217</fpage>
<lpage>219</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Drugs suppressing the renin-angiotensin-aldosterone system (RAAS) are now widely used to treat patients all along the cardiorenal continuum. It supposes that many patients, in particular those with arterial hypertension are treated with converting-enzyme inhibitors and angiotensin receptor blockers for years during which the development and prograssion of cardiorenal disease can be observed. The meaning of this progression in the presence of RAAS suppression requires to be clarified and to be treated in order to diminish the velocity of progression of cardiorenal disease.</p>
</abstract>
</article-meta>
</front>
<body>
<p>The discovery of drugs able to suppress the renin–angiotensin–aldosterone system (RAAS) has greatly contributed to improved quality and duration of life of patients with arterial hypertension, congestive heart failure, chronic kidney disease, post-myocardial infarction and stroke and also in patients with a high global cardiovascular risk profile.<sup><xref ref-type="bibr" rid="bibr1-1470320312439140">1</xref>,<xref ref-type="bibr" rid="bibr2-1470320312439140">2</xref></sup> As a consequence of these positive effects when established cardiovascular and renal disease are present, the indications of RAAS blockers have expanded during recent years to the earlier stages of the cardiorenal continuum particularly in patients with a high added risk due to the clustering of three or more cardiovascular (CV) risk factors, the presence of metabolic syndrome and diabetes and the discovery of early target organ damage.<sup><xref ref-type="bibr" rid="bibr1-1470320312439140">1</xref></sup> It has been clearly shown that treatment of hypertension with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) reduces the risk of developing heart failure<sup><xref ref-type="bibr" rid="bibr3-1470320312439140">3</xref></sup> and also reduces the onset of left ventricular hypertrophy and microalbuminuria in diabetes.<sup><xref ref-type="bibr" rid="bibr4-1470320312439140">4</xref>-<xref ref-type="bibr" rid="bibr6-1470320312439140">6</xref></sup></p>
<p>An important field that is currently receiving research attention is to what extent RAAS blockade offers a continuous protection when maintained along the evolution of cardiorenal continuum and what actions should be taken to improve the degree of blockade to improve the outcome of the patients if cardiorenal disease progresses.<sup><xref ref-type="bibr" rid="bibr7-1470320312439140">7</xref></sup> In this sense, as recently reviewed,<sup><xref ref-type="bibr" rid="bibr8-1470320312439140">8</xref></sup> the development of new heart failure has been seen in patients chronically treated with ACEi and beta-blockers, drugs commonly used to treat developed heart failure. Another example is the development of new-onset albuminuria in patients receiving an ACEi or an ARB for years.<sup><xref ref-type="bibr" rid="bibr9-1470320312439140">9</xref></sup> In the ONTARGET study two-thirds of patients were receiving chronically an ACEi before entering the study and unlike previous studies albuminuria exhibited a progressive increase in all three groups receiving ramipril, telmisartan, and their combination, with the latter group displaying the lowest rate.<sup><xref ref-type="bibr" rid="bibr10-1470320312439140">10</xref></sup></p>
<p>Different reasons may explain this phenomenon of cardiorenal disease development under chronic RAAS blockade. First, although ACEIs and ARBs have been extensively used in patients for decades, the question of how many patients under these treatments actually respond to RAAS inhibition is not usually answered, as common laboratory variables reflecting the degree of RAAS suppression at different levels (such as plasma angiotensin II, or plasma renin activity) are not routinely recorded in clinical practice before and after the initiation of RAAS-blocking agents. The extent of response to treatment has not been quantified in relevant studies of the field,<sup><xref ref-type="bibr" rid="bibr4-1470320312439140">4</xref>,<xref ref-type="bibr" rid="bibr6-1470320312439140">6</xref></sup> so the actual percentage of patients responding to RAAS blockade is not known. Another potential explanation for the above is that use of RAAS blockers at the highest recommended dose for hypertension may simply be inadequate to fully suppress the RAAS. Following the evidence on delay of kidney disease progression with single RAAS blockade,<sup><xref ref-type="bibr" rid="bibr11-1470320312439140">11</xref></sup> various studies in proteinuric nephropathies strongly suggest that supra-high doses of a single agent<sup><xref ref-type="bibr" rid="bibr12-1470320312439140">12</xref>,<xref ref-type="bibr" rid="bibr13-1470320312439140">13</xref></sup> are much more potent to reduce proteinuria. Further, it has been proposed that use of only a single agent acting at one particular site of the RAAS axis (i.e. ACE inhibition or blockade of angiotensin II receptors) may be not enough to prevent the evolution of target organ damage, due to escape of a downstream component of the RAAS. Previous studies had shown that 30–40% of hypertensive patients treated with an ACEI or an ARB may have increased levels of angiotensin II and aldosterone or aldosterone respectively, with deleterious consequences for cardiorenal disease.<sup><xref ref-type="bibr" rid="bibr14-1470320312439140">14</xref>,<xref ref-type="bibr" rid="bibr15-1470320312439140">15</xref></sup> Following this argument, studies with combinations of ACEIs and ARBs,<sup><xref ref-type="bibr" rid="bibr16-1470320312439140">16</xref></sup> addition of a renin inhibitor<sup><xref ref-type="bibr" rid="bibr17-1470320312439140">17</xref></sup> and, even more so, addition of an aldosterone blocker<sup><xref ref-type="bibr" rid="bibr18-1470320312439140">18</xref></sup> have shown impressive results in proteinuria reduction. With regards to patients with heart failure, combinations of ACEIs and ARBs have been shown to have cardiovascular benefits over single RAS blockade.<sup><xref ref-type="bibr" rid="bibr1-1470320312439140">1</xref>,<xref ref-type="bibr" rid="bibr19-1470320312439140">19</xref></sup> Addition of an aldosterone blocker to standard RAS inhibition has also improved all-cause mortality in the Randomized Aldactone Evaluation Study (RALES), Eplerenone Heart Failure Efficacy and Survival Study (EPHESUS) and Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS) study.<sup><xref ref-type="bibr" rid="bibr20-1470320312439140">20</xref>-<xref ref-type="bibr" rid="bibr22-1470320312439140">22</xref></sup> Such approaches of aggressive RAS blockade, however, should be balanced against the possibility that absence of albuminuria indicates another paradigm of kidney disease, i.e. ischaemic nephropathy, and that aggressive RAAS inhibition can also be harmful in some cases.<sup><xref ref-type="bibr" rid="bibr19-1470320312439140">19</xref>,<xref ref-type="bibr" rid="bibr23-1470320312439140">23</xref></sup> The analysis of renal events in the ONTARGET study showed that dual RAAS blockade did not confer any benefit in terms of renal outcomes and significantly increased the risk of dialysis for acute renal failure.<sup><xref ref-type="bibr" rid="bibr10-1470320312439140">10</xref></sup> Furthermore, the Aliskiren Trial In Type 2 diabetes Using cardio-renal Disease Endpoints (ALTITUDE), which was designed to compare the effects of combination treatment of aliskiren and ACEI or ARB versus ACE or ARB alone on cardiovascular and renal outcomes in patients with type 2 diabetes with macroalbuminuria or with eGFR 30–60 ml/min per 1.73 m<sup>2</sup> and microalbuminuria or history of cardiovascular events, was prematurely terminated following the recommendation of the data safety and monitoring committee.<sup><xref ref-type="bibr" rid="bibr24-1470320312439140">24</xref></sup> The reason was the finding of an increase in non-fatal stroke, renal complications, hyperkalaemia and hypotension in the aliskiren group, which can simply reflect the additive effects of hypotension and eGFR reduction when adding potent RAAS blocker in patients with already well-controlled officeblood pressure, mechanisms similar to those seen in ONTARGET.<sup><xref ref-type="bibr" rid="bibr25-1470320312439140">25</xref></sup> Overall, several major outcome trials over the last few years have clearly shown that treatment of hypertensive patients with a blocker of RAAS can protect against the development of cardiovascular and renal damage. A certain number of patients, however, will still progress to the next level of cardiorenal disease despite chronic treatment with RAAS-inhibitors. Increasing the potency of RAAS suppression through high doses or combination of RAAS blockers has also shown to improve cardiac and renal outcomes, but recent studies suggest that certain patient categories may suffer important complications with this approach. Future studies are clearly necessary to clarify which is the best way of increasing RAAS suppression and which patients will have the maximum benefit with minimal complications from this.</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320312439140">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mancia</surname><given-names>G</given-names></name>
<name><surname>De Backer</surname><given-names>G</given-names></name>
<name><surname>Dominiczak</surname><given-names>A</given-names></name><etal/>
</person-group>. <year>2007</year> <article-title>guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title>. <source>J Hypertens</source> <year>2007</year>; <volume>25</volume>: <fpage>1105</fpage>–<lpage>1187</lpage>.</citation>
</ref>
<ref id="bibr2-1470320312439140">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruilope</surname><given-names>LM</given-names></name>
</person-group>. <article-title>Current challenges in the clinical management of hypertension</article-title>. <source>Nat Rev Cardiol</source>. <comment>Epub ahead of print</comment> <year>2011</year>.</citation>
</ref>
<ref id="bibr3-1470320312439140">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verdecchia</surname><given-names>P</given-names></name>
<name><surname>Angeli</surname><given-names>F</given-names></name>
<name><surname>Cavallini</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Blood pressure reduction and renin–angiotensin system inhibition for prevention of congestive heart failure: A meta-analysis</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>679</fpage>–<lpage>688</lpage>.</citation>
</ref>
<ref id="bibr4-1470320312439140">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruggenenti</surname><given-names>P</given-names></name>
<name><surname>Fassi</surname><given-names>A</given-names></name>
<name><surname>Ilieva</surname><given-names>AP</given-names></name><etal/>
</person-group>. <article-title>Preventing microalbuminuria in type 2 diabetes</article-title>. <source>N Engl J Med</source> <year>2004</year>; <volume>351</volume>: <fpage>1941</fpage>–<lpage>1951</lpage>.</citation>
</ref>
<ref id="bibr5-1470320312439140">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruggenenti</surname><given-names>P</given-names></name>
<name><surname>Iliev</surname><given-names>I</given-names></name>
<name><surname>Costa</surname><given-names>GM</given-names></name><etal/>
</person-group>. <article-title>Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)</article-title>. <source>Diabetes Care</source> <year>2008</year>; <volume>31</volume>: <fpage>1629</fpage>–<lpage>1634</lpage>.</citation>
</ref>
<ref id="bibr6-1470320312439140">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haller</surname><given-names>H</given-names></name>
<name><surname>Ito</surname><given-names>S</given-names></name>
<name><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></name><etal/>
</person-group>. <article-title>Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes</article-title>. <source>N Engl J Med</source> <year>2011</year>; <volume>364</volume>: <fpage>907</fpage>–<lpage>917</lpage>.</citation>
</ref>
<ref id="bibr7-1470320312439140">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volpe</surname><given-names>M</given-names></name>
<name><surname>Danser</surname><given-names>AHJ</given-names></name>
<name><surname>Menard</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Inhibition of the renin–angiotensin–aldosterone system (RAAS): Is there room for dual blockade in the cardiorenal continuum?</article-title> <source>J Hypertens</source>. <comment>Epub ahead of print</comment> <year>2012</year>.</citation>
</ref>
<ref id="bibr8-1470320312439140">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gustaffson</surname><given-names>F</given-names></name>
<name><surname>Segura</surname><given-names>J</given-names></name>
<name><surname>Ruilope</surname><given-names>LM</given-names></name>
</person-group>. <article-title>How should we manage heart failure developing in patients treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension diabetes or coronary disease?</article-title> <source>J Hypertens</source> <year>2010</year>; <volume>28</volume>: <fpage>1595</fpage>–<lpage>1598</lpage>.</citation>
</ref>
<ref id="bibr9-1470320312439140">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cerezo</surname><given-names>C</given-names></name>
<name><surname>Ruilope</surname><given-names>LM</given-names></name>
<name><surname>Segura</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Microalbuminuria breakthrough under chronic renin–angiotensin–aldosterone system suppression</article-title>. <source>J Hypertens</source> <year>2012</year>; <volume>30</volume>: <fpage>204</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr10-1470320312439140">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mann</surname><given-names>JF</given-names></name>
<name><surname>Schmieder</surname><given-names>RE</given-names></name>
<name><surname>McQueen</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial</article-title>. <source>Lancet</source> <year>2008</year>; <volume>372</volume>(<issue>9638</issue>): <fpage>547</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr11-1470320312439140">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Khosla</surname><given-names>N</given-names></name>
<name><surname>Bakris</surname><given-names>GL</given-names></name>
</person-group>. <article-title>Antihypertensive therapy in the presence of proteinuria</article-title>. <source>Am J Kidney Dis</source> <year>2007</year>; <volume>49</volume>: <fpage>12</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr12-1470320312439140">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossing</surname><given-names>K</given-names></name>
<name><surname>Schjoedt</surname><given-names>KJ</given-names></name>
<name><surname>Jensen</surname><given-names>BR</given-names></name><etal/>
</person-group>. <article-title>Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria</article-title>. <source>Kidney Int</source> <year>2005</year>; <volume>68</volume>: <fpage>1190</fpage>–<lpage>1198</lpage>.</citation>
</ref>
<ref id="bibr13-1470320312439140">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmieder</surname><given-names>RE</given-names></name>
<name><surname>Klingbeil</surname><given-names>AU</given-names></name>
<name><surname>Fleischmann</surname><given-names>EH</given-names></name><etal/>
</person-group>. <article-title>Additional antiproteinuric effect of ultrahigh dose candesartan: A double-blind, randomized, prospective study</article-title>. <source>J Am Soc Nephrol</source> <year>2005</year>; <volume>16</volume>: <fpage>3038</fpage>–<lpage>3045</lpage>.</citation>
</ref>
<ref id="bibr14-1470320312439140">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Athyros</surname><given-names>VG</given-names></name>
<name><surname>Mikhailidis</surname><given-names>DP</given-names></name>
<name><surname>Kakafika</surname><given-names>AI</given-names></name><etal/>
</person-group>. <article-title>Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: Is oral renin inhibition the solution?</article-title> <source>Expert Opin Pharmacother</source> <year>2007</year>; <volume>8</volume>: <fpage>529</fpage>–<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr15-1470320312439140">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bomback</surname><given-names>AS</given-names></name>
<name><surname>Klemmer</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>The incidence and implications of aldosterone breakthrough</article-title>. <source>Nat Clin Pract Nephrol</source> <year>2007</year>; <volume>3</volume>: <fpage>486</fpage>–<lpage>492</lpage>.</citation>
</ref>
<ref id="bibr16-1470320312439140">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kunz</surname><given-names>R</given-names></name>
<name><surname>Friedrich</surname><given-names>C</given-names></name>
<name><surname>Wolbers</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease</article-title>. <source>Ann Intern Med</source> <year>2008</year>; <volume>148</volume>: <fpage>30</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr17-1470320312439140">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parving</surname><given-names>HH</given-names></name>
<name><surname>Persson</surname><given-names>F</given-names></name>
<name><surname>Lewis</surname><given-names>JB</given-names></name><etal/>
</person-group>. <article-title>Aliskiren combined with losartan in type 2 diabetes and nephropathy</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>2433</fpage>–<lpage>2446</lpage>.</citation>
</ref>
<ref id="bibr18-1470320312439140">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehdi</surname><given-names>UF</given-names></name>
<name><surname>ms-Huet</surname><given-names>B</given-names></name>
<name><surname>Raskin</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy</article-title>. <source>J Am Soc Nephrol</source> <year>2009</year>; <volume>20</volume>: <fpage>2641</fpage>–<lpage>2650</lpage>.</citation>
</ref>
<ref id="bibr19-1470320312439140">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruilope</surname><given-names>LM</given-names></name>
<name><surname>Segura</surname><given-names>J</given-names></name>
</person-group>. <article-title>ARBs and ACEis together in the treatment of hypertension and its complications? Current practical recommendations</article-title>. <source>Expert Opin Pharmacother</source> <year>2010</year>; <volume>11</volume>: <fpage>2619</fpage>–<lpage>2623</lpage>.</citation>
</ref>
<ref id="bibr20-1470320312439140">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pitt</surname><given-names>B</given-names></name>
<name><surname>Zannad</surname><given-names>F</given-names></name>
<name><surname>Remme</surname><given-names>WJ</given-names></name><etal/>
</person-group>. <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators</article-title>. <source>N Engl J Med</source> <year>1999</year>; <volume>341</volume>: <fpage>709</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr21-1470320312439140">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pitt</surname><given-names>B</given-names></name>
<name><surname>Remme</surname><given-names>W</given-names></name>
<name><surname>Zannad</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Eplerenone, a selective aldosterone blocker, in patients with left ventriculardysfunction after myocardial infarction</article-title>. <source>N Engl J Med</source> <year>2003</year>; <volume>348</volume>: <fpage>1309</fpage>–<lpage>1321</lpage>.</citation>
</ref>
<ref id="bibr22-1470320312439140">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zannad</surname><given-names>F</given-names></name>
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
<name><surname>Krum</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Eplerenone in patients with systolic heart failure and mild symptoms</article-title>.<source>N Eng J Med</source> <year>2011</year>; <volume>364</volume>: <fpage>11</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr23-1470320312439140">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarafidis</surname><given-names>PA</given-names></name>
<name><surname>Bakris</surname><given-names>GL</given-names></name>
</person-group>. <article-title>Renin–angiotensin blockade and kidney disease</article-title>. <source>Lancet</source> <year>2008</year>; <volume>372</volume>(<issue>9638</issue>): <fpage>511</fpage>–<lpage>512</lpage>.</citation>
</ref>
<ref id="bibr24-1470320312439140">
<label>24.</label>
<citation citation-type="web">
<article-title>Novartis announces termination of ALTITUDE study with Rasilez®/Tekturna® in high-risk patients with diabetesand renal impairment</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.novartis.com/downloads/newsroom/rasilez-tekturna-information-center/20111220-rasilez-tekturna.pdf">http://www.novartis.com/downloads/newsroom/rasilez-tekturna-information-center/20111220-rasilez-tekturna.pdf</ext-link> (<access-date>accessed 4 January 2012</access-date>).</citation>
</ref>
<ref id="bibr25-1470320312439140">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruilope</surname><given-names>LM</given-names></name>
<name><surname>Segura</surname><given-names>J</given-names></name>
<name><surname>Zamorano</surname><given-names>JL</given-names></name>
</person-group>. <article-title>New clinical concepts after the ONTARGET trial</article-title>. <source>Expert Rev Cardiovasc Ther</source> <year>2011</year>; <volume>9</volume>: <fpage>685</fpage>–<lpage>689</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>